{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:59:22Z","timestamp":1792684762605,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370205 , 82070223"],"award-info":[{"award-number":["82370205 , 82070223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The emergence of chimeric antigen receptor (CAR)-T therapy targeting B cell maturation antigen (BCMA) has improved the prognosis of patients with multiple myeloma (MM); however, the majority of patients eventually experience relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, employing the latest single-cell RNA sequencing technology, we examined 24 bone marrow or peripheral blood samples collected throughout the course of anti-BCMA CAR-T therapy, analyzing a total of 59,725 bone marrow cells and 72,479 peripheral blood cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our findings reveal that tumor cells in relapsed patient exhibit higher expression levels of HSP90B1 and HSPA5, and demonstrate significantly enriched pathways regarding endoplasmic reticulum stress and unfolded protein response. In the analysis of T cells, we observed that patient with impaired effector function and increased expression of immune checkpoints in endogenous T cell are more susceptible to relapse. Notably, T cells from both the bone marrow microenvironment and peripheral blood share highly similar biological characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Overall, this study provides a comprehensive atlas of endogenous immune cells, particularly in the relatively long term, after CAR-T therapy. It offers clinical evidence for a deeper understanding of the internal environment post CAR-T treatment and for identifying mechanisms underlying relapse.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1278749","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:53:11Z","timestamp":1699959191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic car T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of lcar-B38m in relapsed or refractory multiple myeloma: A phase 1, single-arm, open-label, multicenter study in China (Legend-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1970218","article-title":"Comprehensive meta-analysis of anti-bcma chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma","volume":"53","author":"Zhang","year":"2021","journal-title":"Ann Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"Car immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.694","article-title":"Single-cell rna sequencing technologies and applications: A brief overview","volume":"12","author":"Jovic","year":"2022","journal-title":"Clin Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of cd4(+) car T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002328","article-title":"Single-cell multiomics dissection of basal and antigen-specific activation states of cd19-targeted car T cells","volume":"9","author":"Bai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of car-T cells in patients undergoing cd19 car-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0292-x","article-title":"Cellphonedb: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4150","article-title":"Single-cell mrna quantification and differential analysis with census","volume":"14","author":"Qiu","year":"2017","journal-title":"Nat Methods"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.06.043","article-title":"Ucell: robust and scalable single-cell gene signature scoring","volume":"19","author":"Andreatta","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature20123","article-title":"Single-cell rna-seq supports a developmental hierarchy in human oligodendroglioma","volume":"539","author":"Tirosh","year":"2016","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: role in B-cell physiology and Malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"B20","article-title":"Multiple myeloma with T (11,14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of bcma as a resistance mechanism to car T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-bcma car T-cell therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15896","article-title":"Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement","volume":"131","author":"Kubicki","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1002\/cti2.1007","article-title":"Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance","volume":"7","author":"Nikesitch","year":"2018","journal-title":"Clin Transl Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0177-6","article-title":"High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of Malignant plasma cells in multiple myeloma","volume":"8","author":"Chhabra","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3111","article-title":"A grp78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement","volume":"22","author":"Rasche","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1830372","article-title":"Glucose-regulated protein 78 (Grp78) as a potential novel biomarker and therapeutic target in multiple myeloma","volume":"13","author":"Ninkovic","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.3390\/cancers14215340","article-title":"Looking into endoplasmic reticulum stress: the key to drug-resistance of multiple myeloma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between car T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/ijms23010405","article-title":"Cancer-homing car-T cells and endogenous immune population dynamics","volume":"23","author":"Guerra","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.028","article-title":"Single-cell transcriptomic analysis reveals bcma car-T cell dynamics in a patient with refractory primary plasma cell leukemia","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/cells11152274","article-title":"Multifunctional role of S100 protein family in the immune system: an update","volume":"11","author":"Singh","year":"2022","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2924","article-title":"Single-cell transcriptomics reveals immune reconstitution in patients with R\/R T-all\/lbl treated with donor-derived cd7 car-T therapy","volume":"29","author":"Chen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding car T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-beta signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.550879","article-title":"Cd74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease","volume":"15","author":"Borghese","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"B39","doi-asserted-by":"publisher","first-page":"10247","DOI":"10.3390\/ijms231810247","article-title":"Microglial cd74 expression is regulated by tgfbeta signaling","volume":"23","author":"Jahn","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2104426","article-title":"Enriched circulating and tumor-resident tgf-beta(+) regulatory B cells in patients with melanoma promote foxp3(+) tregs","volume":"11","author":"Harris","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1278749\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:53:17Z","timestamp":1699959197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1278749\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2023.1278749"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1278749","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"article-number":"1278749"}}